Recent Investment Analysts’ Ratings Changes for Trevi Therapeutics (TRVI)

Trevi Therapeutics (NASDAQ: TRVI) recently received a number of ratings updates from brokerages and research firms:

• 8/7/2026 – Trevi Therapeutics had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $23.00 price target on the stock.
• 8/7/2026 – Trevi Therapeutics had its price target raised by Oppenheimer Holdings, Inc. from $24.00 to $25.00. They now have an “outperform” rating on the stock.
• 8/7/2026 – Trevi Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $40.00 price target on the stock.
• 8/7/2026 – Trevi Therapeutics had its price target raised by Cantor Fitzgerald from $25.00 to $30.00. They now have an “overweight” rating on the stock.
• 7/25/2026 – Trevi Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/20/2026 – Trevi Therapeutics is now covered by BMO Capital Markets. They set an “outperform” rating and a $36.00 price target on the stock.
• 7/20/2026 – Trevi Therapeutics was upgraded by BMO Capital Markets to “strong-buy”.
• 7/20/2026 – Trevi Therapeutics had its price target raised by B. Riley Financial, Inc. from $21.00 to $31.00. They now have a “buy” rating on the stock.
• 7/20/2026 – Trevi Therapeutics had its price target raised by HC Wainwright from $21.00 to $24.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Trevi Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/20/2026 – Trevi Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.